knowledge -WSS

knowledge

author：focus 2025-09-07 14:04:01 - browse：3192

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

hotspot

WSS

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

CEOs share strategies for surviving biotech slump

Will Ozempic

Ionis drug prevents swelling attacks due to hereditary angioedema

STAT Readout Newsletter: Today's biggest biotech updates

Senate committee scrutinizes Medicare Advantage brokers

leisure time

knowledge

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pharmacists can make shortage drugs, but at what cost?

At least 13 dead in Texas as scorching temps continue

With trial win, GSK could get blood cancer drug back on market

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How climate

How to save PrEP access — and even expand it

The Pandemic Treaty must support building strong health systems

Apple is now the first public company to be valued at $3 trillion

The explosion of genetic testing requires a new approach

focus

Letters to First Opinion on caregivers, digital health, and more

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Ultragenyx gene therapy for rare liver ailment succeeds in late

NIH documents show early flaws of $1.6 billion long Covid program

ASCO: AstraZeneca says CAR

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

focus

Wikipedia

hotspot

explore